cgrpreceptor

Rimegepant (BMS 927711) is a highly potent, oral calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki value of 0.027 nM.

CGRP antagonist 1 is a potent CGRP receptor antagonist with Ki values of 35 nM and IC50 values of 57 nM, respectively.CGRP antagonist 1 can be used for the study of cardiovascular and neurovascular diseases.

Adrenomedullin (AM) (22-52), human acetate is an antagonist of calcitonin generelated peptide receptor in the hindlimb vascular bed of the cat and an adrenomedullin receptor.

Olcegepant (BIBN-4096) is an effective and selective non-peptide calcitonin gene-related peptide 1 (CGRP1) receptor antagonist (IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP).

ML230 is a selective ATP-binding cassette (ABC) transporter ABCG2 inhibitor. It 36-fold selective for ABCG2 over ABCB1 (EC50s: 0.13 μM and 4.65 μM, respectively).

Ubrogepant (MK-1602) is a calcitonin gene-related peptide receptor antagonist used in acute migraine treatment studies.

Atogepant (MK-8031) is an orally available, selective and potent calcitonin gene-related peptide receptor (CGRP) antagonist for the study of migraine.

Vazegepant (Zavegepant) is an orally available and selective antagonist of the calcitonin gene-related peptide CGRP receptor for pain relief and may be used in the study of migraine.

MK-3207 Hydrochloride (MK-3207 HCl) is a potent CGRP receptor antagonist with IC50 and Kiof 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. Phase 2.

Galcanezumab is a humanized IgG4 monoclonal antibody targeting the CGRP ligand, which binds to the ligand calcitonin gene-related peptide. Galcanezumab can be used to prevent and treat migraines or cluster headaches.

Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attacks.

α-CGRP (mouse, rat) TFA, a neuropeptide belonging to the calcitonin gene-related peptide (CGRP) family, is predominantly located at neuromuscular junctions and functions as a potent vasodilator. Peripheral administration of α-CGRP (mouse, rat) TFA may result in decreased blood pressure and elevated heart rate, in addition to the relaxation of colonic smooth muscle. This compound shows promising utility in the investigation of cardiovascular, pro-inflammatory, migraine, and metabolic conditions [1] [2] [3].

Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.

Calcitonin (salmon), a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.

Calcitonin(salmon)Acetate(47931-85-1(free base))(Salmon calcitonin) , a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.

HCGRP-(8-37) acetate is a human calcitonin gene-related peptide (hCGRP) fragment acetate and also an antagonist of CGRP receptor.

CGRP 8-37 (rat) is a CGRP receptor antagonist, a CGRP fragment with potential anti-injury effects that induces arterial relaxation.

β-CGRP, human acetate is one of calcitonin peptides and acts via the complex of receptor-activity-modifying protein (RAMP) and calcitonin-receptor-like receptor (CRLR) (IC50s: 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells).

Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a selective calcitonin gene-related peptide 1 (CGRP1) receptor antagonist with an IC50=0.03 nM and Ki=14.4 pM.

Telcagepant (MK-0974) is an oral calcitonin gene-related peptide receptor (CGRP) antagonist that blocks CGRP receptors and reduces neurotransmission in the central nervous system and is used in the study of migraines and for pain relief.

Calcitonin-13C6,15N4 trifluoroacetic acid is a version of calcitonin (salmon) labeled with carbon-13 and nitrogen-15. This hormone regulates calcium and acts dualistically as an agonist to both amylin and calcitonin receptors, promoting bone formation while inhibiting bone resorption.

CGRP antagonist 7 is a potent calcitonin gene-related peptide receptor (CGRP) antagonist with a Ki value of 0.029 nM. It effectively inhibits CGRP receptor-mediated cyclic adenosine monophosphate (cAMP) production, with an IC50 value of 1.5 nM. This compound is useful in migraine research.

Amylin agonist 1 (Example 239a) is an agonist of amylin receptor 3 (AMY3R) with an EC50 of 6.17 nM for stimulating cellular cAMP production. It also acts as an agonist of the calcitonin receptor (CTR) with an EC50 of 8.58 nM. Amylin agonist 1 is applicable for research in type 2 diabetes and obesity.

Rimegepant (BMS-927711) hemisulfate is a potent, orally active selective competitive antagonist of the calcitonin gene-related peptide (CGRP) receptor, with a Ki of 0.027 nM and an IC50 of 0.14 nM for the hCGRP receptor. Rimegepant hemisulfate is utilized in migraine research.